Haemophilia a: Pharmacoeconomic review of prophylaxis treatment versus on-demand

Scientific World Journal

Volumn 2015, Issue , 2015, Pages

  Unim, Brigid ^a   Veneziano, Maria Assunta ^b   Boccia, Antonio ^a   Ricciardi, Walter ^b   La Torre, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKLIST; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MEDLINE; META ANALYSIS (TOPIC); QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SCOPUS; SEARCH ENGINE; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMICS; MALE;

BLOOD CLOTTING FACTOR 8;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FACTOR VIII; HEALTH CARE COSTS; HEMOPHILIA A; HUMANS; MALE;

EID: 84921468586     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2015/596164     Document Type: Review

References (26)

1. F. Abbonizio, A. Giampaolo, C. Chelucci, R. Arcieri, and H. J. Hassan, and quot;Associazione ItalianaCentri Emofilia (AICE). Registro Nazionale Coagulopatie Congenite, and " Tech. Rep. Rapporti ISTISAN 14/12, Istituto Superiore di Sanità, Roma, Italy, 2012.
2. W. Schramm, S. Royal, B. Kroner et al., and quot;Clinical outcomes and resource utilization associated with haemophilia care in Europe, and " Haemophilia, vol. 8, no. 1, pp. 33-43, 2002.
3. M. N. Di Minno, G. Di Minno, M. Di Capua, A. M. Cerbone, and A. Coppola, and quot;Cost of care of haemophilia with inhibitors, and " Haemophilia, vol. 16, no. 1, pp. e190-e201, 2010.
4. M. M. Ullman and W. K. Hoots, and quot;Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors, and " Haemophilia, vol. 12, no. 6, pp. 74-80, 2006.
5. C. Negrini, F. Daniele, M. E. Mancuso, G. F. Rivolta, and A. Tagliaferri, and quot;Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura, and " PharmacoEconomics-Italian Research Articles, vol. 8, no. 1, pp. 33-44, 2006.
6. B. T. Colvin, J. Astermark, K. Fischer et al., and quot;European principles of haemophilia care, and " Haemophilia, vol. 14, no. 2, pp. 361-374, 2008.
7. A. Tagliaferri, M. Franchini, A. Coppola et al., and quot;Effects of secondary prophylaxis started in adolescent and adult haemophiliacs, and " Haemophilia, vol. 14, no. 5, pp. 945-951, 2008.
8. M. J. Manco-Johnson, T. C. Abshire, A. D. Shapiro et al., and quot;Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, and " The New England Journal of Medicine, vol. 357, no. 6, pp. 535-544, 2007.
9. M. F. Drummond, M. J. Sculpher, G. Torrance, J. OBrien, and G. L. Stoddart, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, New York, NY, USA, 3rd edition, 2005.
10. J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.
11. M. F. Drummond and T. O. Jefferson, and quot;Guidelines for authors and peer reviewers of economic submissions to the BMJ, and " British Medical Journal, vol. 313, no. 7052, pp. 275-283, 1996.
12. G. La Torre, N. Nicolotti, C. de Waure, and W. Ricciardi, and quot;Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine, and " Journal of Public Health, vol. 19, no. 2, pp. 103-111, 2011.
13. A. Liberati, D. G. Altman, J. Tetzlaff et al., and quot;The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, and " Italian Journal of Public Health, vol. 6, no. 4, pp. 354-391, 2009.
14. A. H. Miners, C. A. Sabin, K. H. Tolley, and C. A. Lee, and quot;Costutility analysis of primary prophylaxis versus treatment ondemand for individuals with severe haemophilia, and " PharmacoEconomics, vol. 20, no. 11, pp. 759-774, 2002.
15. A. H. Miners, and quot;Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A, and " Haemophilia, vol. 15, no. 4, pp. 881-887, 2009.
16. N. Risebrough, P. Oh, V. Blanchette, J. Curtin, J. Hitzler, and B. M. Feldman, and quot;Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A, and " Haemophilia, vol. 14, no. 4, pp. 743-752, 2008.
17. B. Lippert, K. Berger, E. Berntorp et al., and quot;Cost effectiveness of haemophilia treatment: a cross-national assessment, and " Blood Coagulation and Fibrinolysis, vol. 16, no. 7, pp. 477-485, 2005.
18. G. L. Colombo, S. di Matteo, M. Elisa Mancuso, and E. Santagostino, and quot;Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A, and " ClinicoEconomics and Outcomes Research, vol. 3, no. 1, pp. 55-61, 2011.
19. S. Capri and W. Ricciardi, and quot;Advate nel trattamento dellemofilia A-analisi costo-efficacia della terapia on-demand vs. profilassi basata sullemivita del prodotto, and " The Italian Journal of Public Health, vol. 8, no. 2, pp. S61-S67, 2011.
20. A. H. Miners, C. A. Sabin, C. H. Tolley, C. Jenkinson, P. Kind, and C. A. Lee, and quot;Assessing health-related quality-of-life in individuals with haemophilia, and " Haemophilia, vol. 5, no. 6, pp. 378-385, 1999.
21. A. Farrugia, J. Cassar, M. C. Kimber et al., and quot;Treatment for life for severe haemophilia A: a cost-utility model for prophylaxis versus on-demand treatment, and " Haemophilia, vol. 19, no. 4, pp. e228-e238, 2013.
22. K. Kurnik, C. Bidlingmaier, W. Engl, H. Chehadeh, B. Reipert, and G. Auerswald, and quot;New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development, and " Haemophilia, vol. 16, no. 2, pp. 256-262, 2010.
23. A. Srivastava, A. K. Brewer, E. P. Mauser-Bunschoten et al., and quot;Guidelines for the management of hemophilia, and " Haemophilia, vol. 19, no. 1, pp. e1-e47, 2013.
24. A. Coppola, A. Tagliaferri, M. Di Capua, and M. Franchini, and quot;Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges, and " Seminars inThrombosis and Hemostasis, vol. 38, no. 1, pp. 79-94, 2012.
25. M. Richards, M. Williams, E. Chalmers et al., and quot;A United Kingdom haemophilia centre doctors organization guideline approved by the British committee for standards in haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A, and " British Journal of Haematology, vol. 149, no. 4, pp. 498-507, 2010.
26. A. H. Miners, and quot;Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?" Haemophilia, vol. 19, no. 2, pp. 174-180, 2013.